peginterferon beta-1a

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

The Containing Coronavirus Disease 19 (COVID-19) Trial

An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)

STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years

DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Plegridy Satisfaction Study in Participants

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Plegridy Observational Program

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies